#METABOLOMICS WORKBENCH jad2033_20230622_094058 DATATRACK_ID:4109 STUDY_ID:ST002752 ANALYSIS_ID:AN004465 PROJECT_ID:PR001509
VERSION             	1
CREATED_ON             	June 27, 2023, 11:15 am
#PROJECT
PR:PROJECT_TITLE                 	Biomolecular condensates create phospholipid-enriched microenvironments
PR:PROJECT_TYPE                  	Metabolomics of in vitro condensates
PR:PROJECT_SUMMARY               	Proteins and RNA are able to phase separate from the aqueous cellular
PR:PROJECT_SUMMARY               	environment to form sub-cellular compartments called condensates. This process
PR:PROJECT_SUMMARY               	results in a protein-RNA mixture that is chemically distinct from the
PR:PROJECT_SUMMARY               	surrounding aqueous phase. Here we use mass spectrometry to characterize the
PR:PROJECT_SUMMARY               	metabolomes of condensates. To test this, we prepared mixtures of
PR:PROJECT_SUMMARY               	phase-separated proteins and cellular metabolites and identified metabolites
PR:PROJECT_SUMMARY               	enriched in the condensate phase. These proteins included SARS-CoV-2
PR:PROJECT_SUMMARY               	nucleocapsid, as well as low complexity domains of MED1 and HNRNPA1.
PR:INSTITUTE                     	Cornell University
PR:DEPARTMENT                    	Department of Pharmacology
PR:LABORATORY                    	Dr. Samie Jaffrey
PR:LAST_NAME                     	Dumelie
PR:FIRST_NAME                    	Jason
PR:ADDRESS                       	1300 York Ave, LC-524, New York City, NY
PR:EMAIL                         	jdumes98@gmail.com
PR:PHONE                         	6465690174
PR:FUNDING_SOURCE                	This work was supported by the National Institutes of Health grants R35NS111631
PR:FUNDING_SOURCE                	and R01CA186702 (S.R.J.); R01AR076029, R21ES032347 and R21NS118633 (Q.C.); and
PR:FUNDING_SOURCE                	NIH P01 HD067244 and support from the Starr Cancer Consortium I13-0037 (S.S.G.).
PR:PUBLICATIONS                  	Under revision
PR:CONTRIBUTORS                  	Jason G. Dumelie, Qiuying Chen, Dawson Miller, Nabeel Attarwala, Steven S. Gross
PR:CONTRIBUTORS                  	and Samie R. Jaffrey1
#STUDY
ST:STUDY_TITLE                   	Biomolecular condensates create phospholipid-enriched microenvironments (Part 7
ST:STUDY_TITLE                   	- reversed phase experiment set 2)
ST:STUDY_TYPE                    	Metabolomes of in vitro synthesized condensates
ST:STUDY_SUMMARY                 	Proteins and RNA are able to phase separate from the aqueous cellular
ST:STUDY_SUMMARY                 	environment to form sub-cellular compartments called condensates. This process
ST:STUDY_SUMMARY                 	results in a protein-RNA mixture that is chemically distinct from the
ST:STUDY_SUMMARY                 	surrounding aqueous phase. In this project we used mass spectrometry to
ST:STUDY_SUMMARY                 	characterize the metabolomes of condensates. To test this, we prepared mixtures
ST:STUDY_SUMMARY                 	of phase-separated proteins and cellular metabolites and identified metabolites
ST:STUDY_SUMMARY                 	enriched in the condensate phase. These proteins included SARS-CoV-2
ST:STUDY_SUMMARY                 	nucleocapsid, as well as low complexity domains of MED1 and HNRNPA1. In this
ST:STUDY_SUMMARY                 	sub-study, we examined the metabolomes of the mouse liver samples that were used
ST:STUDY_SUMMARY                 	to conduct the condensate metabolome experiment described above.
ST:INSTITUTE                     	Cornell University
ST:DEPARTMENT                    	Department of Pharmacology
ST:LABORATORY                    	Dr. Samie Jaffrey
ST:LAST_NAME                     	Dumelie
ST:FIRST_NAME                    	Jason
ST:ADDRESS                       	1300 York Ave, LC-524, New York City, NY
ST:EMAIL                         	jdumes98@gmail.com
ST:PHONE                         	6465690174
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	-	RP_experiment_set_2_1	Input_metabolites:mouse liver	Used for MS/MS fragmentation=Yes; RAW_FILE_NAME=040323 ZLiverafterRun liver msms neg_P1-E-2_1_409.xml
SUBJECT_SAMPLE_FACTORS           	-	RP_experiment_set_2_2	Input_metabolites:mouse liver	Used for MS/MS fragmentation=Yes; RAW_FILE_NAME=040323ZLiverafterRUNPOSmsms_P1-E-2_1_407.xml
SUBJECT_SAMPLE_FACTORS           	-	RP_experiment_set_2_3	Input_metabolites:mouse liver	Used for MS/MS fragmentation=Yes; RAW_FILE_NAME=040623LiverNEG-SPLZ1  PIPE_P1-E-2_1_417.xml
SUBJECT_SAMPLE_FACTORS           	-	RP_experiment_set_2_4	Input_metabolites:mouse liver	Used for MS/MS fragmentation=Yes; RAW_FILE_NAME=040623LiverNEG-SPLZ1  PS2_P1-E-2_1_425.xml
SUBJECT_SAMPLE_FACTORS           	-	RP_experiment_set_2_5	Input_metabolites:mouse liver	Used for MS/MS fragmentation=Yes; RAW_FILE_NAME=040623LiverPOS-SPLZ1_P1-E-2_1_413.xml
SUBJECT_SAMPLE_FACTORS           	-	RP_experiment_set_2_6	Input_metabolites:Re-run of MED1 Condensate Sample 5 (from study ST002352)	Used for MS/MS fragmentation=No; RAW_FILE_NAME=JASON 52b_P1-E-1_1_391.xml
SUBJECT_SAMPLE_FACTORS           	-	RP_experiment_set_2_7	Input_metabolites:mouse liver	Used for MS/MS fragmentation=No; RAW_FILE_NAME=L1-POS_P1-E-1_1_479.xml
SUBJECT_SAMPLE_FACTORS           	-	RP_experiment_set_2_8	Input_metabolites:mouse liver	Used for MS/MS fragmentation=No; RAW_FILE_NAME=L2-POS_P1-E-2_1_476.xml
SUBJECT_SAMPLE_FACTORS           	-	RP_experiment_set_2_9	Input_metabolites:mouse liver	Used for MS/MS fragmentation=No; RAW_FILE_NAME=LiverSPL neg pc sm pi half  calibrant_P1-E-2_1_463.xml
SUBJECT_SAMPLE_FACTORS           	-	RP_experiment_set_2_10	Input_metabolites:mouse liver	Used for MS/MS fragmentation=No; RAW_FILE_NAME=LiverSPL neg pc sm pi_P1-E-1_1_457.xml
#COLLECTION
CO:COLLECTION_SUMMARY            	Mouse metabolites were collected from the liver of female mice using methanol
CO:COLLECTION_SUMMARY            	extraction. After euthanizing a mouse, the liver was immediately frozen in
CO:COLLECTION_SUMMARY            	liquid nitrogen. We then used cold 80% methanol to extract metabolites. First, 1
CO:COLLECTION_SUMMARY            	ml of 80% methanol was added to the liver and incubated for 10 min at -20oC.
CO:COLLECTION_SUMMARY            	Glass beads were added to the liver and then the liver was lysed by bead-beating
CO:COLLECTION_SUMMARY            	for 45 s using a Tissuelyser cell disrupter (Qiagen). The lysate was incubated
CO:COLLECTION_SUMMARY            	for 10 min at -20oC and centrifuged (13200 rpm, 5 min) to separate metabolites
CO:COLLECTION_SUMMARY            	from macromolecules. The supernatant was collected and 200 µl of 80% methanol
CO:COLLECTION_SUMMARY            	was added to the pellet. The incubation, shaking and centrifugation steps were
CO:COLLECTION_SUMMARY            	repeated twice to extract more metabolites from the pellet. The three
CO:COLLECTION_SUMMARY            	supernatants were combined and centrifuged (14000 rpm, 10 min) to separate any
CO:COLLECTION_SUMMARY            	remaining macromolecules from the metabolites. The combined supernatants were
CO:COLLECTION_SUMMARY            	dried using a SpeedVac Concentrator (Savant, SPD131DDA) at 25oC and the dried
CO:COLLECTION_SUMMARY            	metabolite samples were stored at -80oC.
CO:SAMPLE_TYPE                   	Liver
CO:COLLECTION_METHOD             	80% methanol
CO:STORAGE_CONDITIONS            	-80℃
#TREATMENT
TR:TREATMENT_SUMMARY             	Metabolites were extracted from mouse livers as discussed in collection. No
TR:TREATMENT_SUMMARY             	special treatment was performed on the mice.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Dried-down extracts were reconstituted in 150 µl 70% acetonitrile, at a
SP:SAMPLEPREP_SUMMARY            	relative protein concentration of ~ 2 µg/µl. These were were injected (4 µl)
SP:SAMPLEPREP_SUMMARY            	for LC/MS-based targeted metabolite profiling.
SP:PROCESSING_STORAGE_CONDITIONS 	-80℃
SP:EXTRACT_STORAGE               	-80℃
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	Chromatography of metabolites utilized reversed phase chromatography on a
CH:CHROMATOGRAPHY_SUMMARY        	Agilent ZORBAX Eclipse Plus C18, 100 × 2.1 mm, 1.8 μm. Mobile phases consisted
CH:CHROMATOGRAPHY_SUMMARY        	of (A) 10 mM ammonium formate with 5 μM Agilent deactivator additive in 5:3:2
CH:CHROMATOGRAPHY_SUMMARY        	water:acetonitrile:2-propanol and (B) 10 mM ammonium formate in 1:9:90
CH:CHROMATOGRAPHY_SUMMARY        	water:acetonitrile:2-propanol. Column temperature was set at 60°C and
CH:CHROMATOGRAPHY_SUMMARY        	autosampler temperature was at 20°C. The flow rate was 0.4 mL/min. The
CH:CHROMATOGRAPHY_SUMMARY        	following gradient was applied: 0 min, 15% B; 0-2.5 min, to 50% B; 2.5-2.6 min,
CH:CHROMATOGRAPHY_SUMMARY        	to 57%, 2.6-9 min, to 70% B; 9-9.1 min, to 93% B; 9.1-11.1 min, to 96%; 11.1-
CH:CHROMATOGRAPHY_SUMMARY        	15min, 100% B; 15-20 min, 15% B.
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Agilent Model 1290 Infinity II liquid chromatography system
CH:COLUMN_NAME                   	Cogent Diamond Hydride (150 × 2.1 mm, 4um)
CH:SOLVENT_A                     	50% water/30% acetonitrile/20% isopropanol;10 mM ammonium formate with 5 µM
CH:SOLVENT_A                     	Agilent deactivator additive
CH:SOLVENT_B                     	1% water/9% acetonitrile/90% isopropanol;10 mM ammonium formate
CH:FLOW_GRADIENT                 	0 min, 15% B; 0-2.5 min, to 50% B; 2.5-2.6 min, to 57%, 2.6-9 min, to 70% B;
CH:FLOW_GRADIENT                 	9-9.1 min, to 93% B; 9.1-11.1 min, to 96%; 11.1- 15min, 100% B; 15-20 min, 15%
CH:FLOW_GRADIENT                 	B.
CH:FLOW_RATE                     	0.4 mL/min
CH:COLUMN_TEMPERATURE            	60
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Bruker Impact HD
MS:INSTRUMENT_TYPE               	QTOF
MS:MS_TYPE                       	Other
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	The Bruker Impact II QTOF was equipped with a vacuum insulated probe heated
MS:MS_COMMENTS                   	electrospray ionization source (VIP-HESI) (Bruker Daltonics, Billerica, USA) to
MS:MS_COMMENTS                   	identify representative lipid structures using auto-MS/MS with and without
MS:MS_COMMENTS                   	scheduled precursor list fragmentation. Fragments were compared with those
MS:MS_COMMENTS                   	deposited in LIPID MAPS, HMDB and MassBank
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	Ion abundance (max peak height)
MS_METABOLITE_DATA_START
Samples	RP_experiment_set_2_1	RP_experiment_set_2_2	RP_experiment_set_2_3	RP_experiment_set_2_4	RP_experiment_set_2_5	RP_experiment_set_2_6	RP_experiment_set_2_7	RP_experiment_set_2_8	RP_experiment_set_2_9	RP_experiment_set_2_10
Factors	Input_metabolites:mouse liver	Input_metabolites:mouse liver	Input_metabolites:mouse liver	Input_metabolites:mouse liver	Input_metabolites:mouse liver	Input_metabolites:Re-run of MED1 Condensate Sample 5 (from study ST002352)	Input_metabolites:mouse liver	Input_metabolites:mouse liver	Input_metabolites:mouse liver	Input_metabolites:mouse liver
PC 34:2		700414			692222		696318	686078		
PC O-36:4		90484			10186		7116	59960		
SM d34:0		3112			3796		4220	9596		
SM d34:1		201538			81174		116556	307152		
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	Chemical Formula	Target Mass	Retention time (median)
PC 34:2	C42H80NO8P	757.5622	7.6
PC O-36:4	C44H82NO7P	767.5829	8.1
SM d34:0	C39H81N2O6P	704.583225	7.3
SM d34:1	C39H79N2O6P	702.567575	6.9
METABOLITES_END
#END